[8-K] Viridian Therapeutics, Inc. Reports Material Event
Viridian Therapeutics (VRDN) filed an 8-K to disclose a collaboration and license agreement signed 30 Jul 2025 with Japan-based Kissei Pharmaceutical covering two IGF-1R monoclonal antibodies, veligrotug and VRDN-003, for thyroid eye disease and other potential indications in Japan. Kissei receives exclusive Japanese development and commercialization rights and a limited non-exclusive manufacturing right; Viridian retains global rights elsewhere and will supply product.
Financial terms: Kissei will pay $70 million upfront. Viridian is eligible for up to $315 million in development, regulatory and sales milestones. Tiered royalties in the low-20% to mid-30% range on future Japanese sales will follow launch. Kissei funds Japanese clinical, regulatory and commercial activities under joint-steering oversight, reducing Viridian鈥檚 cash burden.
Strategic impact: The agreement delivers immediate, non-dilutive capital, extends cash runway and externally validates VRDN-003/veligrotug while preserving all ex-Japan upside. Key execution risks include dependence on Kissei鈥檚 development success and Viridian鈥檚 ongoing manufacturing obligations.
Viridian Therapeutics (VRDN) ha presentato un modulo 8-K per comunicare un accordo di collaborazione e licenza firmato il 30 luglio 2025 con la giapponese Kissei Pharmaceutical, riguardante due anticorpi monoclonali IGF-1R, veligrotug e VRDN-003, per la malattia oculare tiroidea e altre potenziali indicazioni in Giappone. Kissei ottiene i diritti esclusivi di sviluppo e commercializzazione in Giappone e un diritto di produzione limitato non esclusivo; Viridian mantiene i diritti globali per gli altri territori e fornir脿 il prodotto.
Termini finanziari: Kissei pagher脿 un anticipo di 70 milioni di dollari. Viridian potr脿 ricevere fino a 315 milioni di dollari in milestone di sviluppo, regolatorie e di vendita. Dopo il lancio, saranno applicate royalty a scaglioni nella fascia dal basso 20% al medio 30% sulle vendite future in Giappone. Kissei finanzier脿 le attivit脿 cliniche, regolatorie e commerciali in Giappone sotto una supervisione congiunta, riducendo l'onere finanziario per Viridian.
Impatto strategico: L'accordo fornisce capitale immediato e non diluitivo, estende la liquidit脿 disponibile e convalida esternamente VRDN-003/veligrotug, preservando tutti i potenziali guadagni al di fuori del Giappone. I principali rischi di esecuzione includono la dipendenza dal successo dello sviluppo da parte di Kissei e gli obblighi continui di produzione di Viridian.
Viridian Therapeutics (VRDN) present贸 un formulario 8-K para revelar un acuerdo de colaboraci贸n y licencia firmado el 30 de julio de 2025 con la japonesa Kissei Pharmaceutical, que abarca dos anticuerpos monoclonales IGF-1R, veligrotug y VRDN-003, para la enfermedad ocular tiroidea y otras indicaciones potenciales en Jap贸n. Kissei recibe los derechos exclusivos de desarrollo y comercializaci贸n en Jap贸n y un derecho limitado de fabricaci贸n no exclusivo; Viridian mantiene los derechos globales fuera de Jap贸n y suministrar谩 el producto.
T茅rminos financieros: Kissei pagar谩 un anticipo de 70 millones de d贸lares. Viridian es elegible para recibir hasta 315 millones de d贸lares en hitos de desarrollo, regulatorios y de ventas. Despu茅s del lanzamiento, se aplicar谩n regal铆as escalonadas en un rango de bajo 20% a medio 30% sobre las ventas futuras en Jap贸n. Kissei financiar谩 las actividades cl铆nicas, regulatorias y comerciales en Jap贸n bajo una supervisi贸n conjunta, reduciendo la carga financiera de Viridian.
Impacto estrat茅gico: El acuerdo proporciona capital inmediato y no dilutivo, extiende la liquidez y valida externamente VRDN-003/veligrotug, preservando todo el potencial fuera de Jap贸n. Los principales riesgos de ejecuci贸n incluyen la dependencia del 茅xito del desarrollo por parte de Kissei y las obligaciones continuas de fabricaci贸n de Viridian.
Viridian Therapeutics(VRDN)電� 2025雲� 7鞗� 30鞚� 鞚茧掣 旮半皹鞚� Kissei Pharmaceutical瓿� 臧戩儊靹� 鞎堧硲歃� 氚� 旮绊儉 鞛犾灛鞝� 鞝侅潙歃濎潉 鞙勴暅 霊� 臧�歆� IGF-1R 雼伌搿犿暛觳挫澑 veligrotug鞕� VRDN-003鞐� 甏�頃� 順戨牓 氚� 霛检澊靹犾姢 瓿勳暯鞚� 觳搓舶頄堧嫟瓿� 8-K 氤搓碃靹滊ゼ 韱淀暣 瓿奠嫓頄堨姷雼堧嫟. 碍颈蝉蝉别颈电� 鞚茧掣 雮� 霃呾爯鞝� 臧滊皽 氚� 靸侅梾頇� 甓岆Μ鞕� 鞝滍暅鞝� 牍勲弲鞝愳爜 鞝滌“ 甓岆Μ毳� 攵�鞐皼鞙茧┌, Viridian鞚� 鞚茧掣 鞕� 鞝� 靹戈硠 甓岆Μ毳� 鞙犾頃橁碃 鞝滍拡鞚� 瓿店笁頃╇媹雼�.
鞛 臁瓣贝: 碍颈蝉蝉别颈电� 7,000毵� 雼煬鞚� 靹犽秷旮�鞚� 歆�旮夗暕雼堧嫟. Viridian鞚� 臧滊皽, 攴滌牅 氚� 韺愲Г 毵堨澕鞀ろ啢鞙茧 斓滊寑 3鞏� 1,500毵� 雼煬毳� 氚涭潉 鞛愱博鞚� 鞛堨姷雼堧嫟. 於滌嫓 頉� 鞚茧掣 雮� 氙鸽灅 毵れ稖鞐� 雽�頃� 20% 齑堧皹鞐愳劀 30% 欷戨皹雽�鞚� 雼硠氤� 搿滌棿韹�臧� 鞝侅毄霅╇媹雼�. 碍颈蝉蝉别颈电� 瓿惦彊 鞖挫榿 臧愲弲 頃橃棎 鞚茧掣 雮� 鞛勳儊, 攴滌牅 氚� 靸侅梾 頇滊彊鞚� 鞛愱笀 歆�鞗愴晿鞐� Viridian鞚� 順勱笀 攵�雼挫潉 欷勳瀰雼堧嫟.
鞝勲灥鞝� 鞓來枼: 鞚� 瓿勳暯鞚� 歃夑皝鞝侅澊瓿� 頋劃霅橃 鞎婋姅 鞛愲掣鞚� 鞝滉车頃橂┌, 順勱笀 鞖挫毄 旮瓣皠鞚� 鞐办灔頃橁碃 VRDN-003/veligrotug毳� 鞕鸽秬鞐愳劀 瓴�歃濏晿電� 霃欖嫓鞐� 鞚茧掣 鞕� 氇摖 鞛犾灛鞝� 鞚挫澋鞚� 氤挫〈頃╇媹雼�. 欤检殧 鞁ろ枆 鞙勴棙鞚� Kissei鞚� 臧滊皽 靹标车 鞚橃〈靹标臣 Viridian鞚� 歆�靻嶌爜鞚� 鞝滌“ 鞚橂鞛呺媹雼�.
Viridian Therapeutics (VRDN) a d茅pos茅 un formulaire 8-K pour divulguer un accord de collaboration et de licence sign茅 le 30 juillet 2025 avec la soci茅t茅 japonaise Kissei Pharmaceutical, portant sur deux anticorps monoclonaux IGF-1R, veligrotug et VRDN-003, destin茅s 脿 la maladie oculaire thyro茂dienne et 脿 d'autres indications potentielles au Japon. Kissei obtient les droits exclusifs de d茅veloppement et de commercialisation au Japon ainsi qu'un droit de fabrication limit茅 non exclusif ; Viridian conserve les droits mondiaux hors Japon et fournira le produit.
Conditions financi猫res : Kissei versera un paiement initial de 70 millions de dollars. Viridian peut recevoir jusqu'脿 315 millions de dollars en jalons de d茅veloppement, r茅glementaires et commerciaux. Des redevances 茅chelonn茅es allant de la plage basse des 20 % 脿 la moyenne des 30 % seront appliqu茅es sur les ventes futures au Japon apr猫s le lancement. Kissei financera les activit茅s cliniques, r茅glementaires et commerciales au Japon sous supervision conjointe, r茅duisant ainsi la charge financi猫re de Viridian.
Impact strat茅gique : Cet accord apporte un capital imm茅diat non dilutif, prolonge la tr茅sorerie disponible et valide ext茅rieurement VRDN-003/veligrotug tout en pr茅servant tous les avantages hors Japon. Les principaux risques d'ex茅cution incluent la d茅pendance au succ猫s du d茅veloppement par Kissei et les obligations continues de fabrication de Viridian.
Viridian Therapeutics (VRDN) hat eine 8-K-Meldung eingereicht, um eine am 30. Juli 2025 unterzeichnete Kooperations- und Lizenzvereinbarung mit dem japanischen Unternehmen Kissei Pharmaceutical offenzulegen. Diese betrifft zwei IGF-1R monoklonale Antik枚rper, veligrotug und VRDN-003, f眉r die Schilddr眉senaugenkrankheit und weitere potenzielle Indikationen in Japan. Kissei erh盲lt exklusive japanische Entwicklungs- und Vermarktungsrechte sowie ein begrenztes nicht-exklusives Herstellungsrecht; Viridian beh盲lt die globalen Rechte au脽erhalb Japans und wird das Produkt liefern.
Finanzielle Bedingungen: Kissei zahlt eine Vorauszahlung von 70 Millionen US-Dollar. Viridian kann bis zu 315 Millionen US-Dollar an Entwicklungs-, Zulassungs- und Verkaufsmeilensteinen erhalten. Nach Markteinf眉hrung folgen gestaffelte Lizenzgeb眉hren im niedrigen 20%- bis mittleren 30%-Bereich auf zuk眉nftige japanische Verk盲ufe. Kissei finanziert die klinischen, regulatorischen und kommerziellen Aktivit盲ten in Japan unter gemeinsamer Steuerung, was die finanzielle Belastung f眉r Viridian reduziert.
Strategische Auswirkungen: Die Vereinbarung bringt sofortiges, nicht verw盲sserndes Kapital, verl盲ngert die finanzielle Reichweite und validiert VRDN-003/veligrotug extern, w盲hrend alle Chancen au脽erhalb Japans erhalten bleiben. Wesentliche Ausf眉hrungsrisiken sind die Abh盲ngigkeit vom Entwicklungserfolg Kisseis und Viridians fortlaufende Herstellungsverpflichtungen.
- None.
- None.
Insights
TL;DR: $70 m upfront and rich royalties provide non-dilutive cash and regional validation; execution remains Japan-dependent.
The deal injects $70 m cash immediately鈥攔oughly equal to ~20-25% of Viridian鈥檚 2024 year-end cash burn鈥攚ithout equity dilution. Potential $315 m milestones plus up-to mid-30% royalties create meaningful long-term optionality if veligrotug/VRDN-003 succeed in Japan. Viridian off-loads costly local trials and commercial build-out, improving capital efficiency. Retaining global rights keeps future M&A optional. Risks: all economics outside the upfront are contingent on Japanese regulatory approval and market adoption; Viridian must still manufacture product, exposing it to supply-chain and COGS risk. Overall, the agreement is strategically and financially accretive.
TL;DR: Classic territory out-license secures cash runway and confirms asset value; limited to Japan and milestone-heavy.
This structure mirrors recent ophthalmology out-licenses, with an attractive royalty slope (>20%) that suggests confidence in premium pricing. Kissei gains a differentiated biologic for an underserved indication, while Viridian accelerates geographic expansion via a local player experienced with niche hospital markets. Milestone stack is back-loaded to commercialization, aligning incentives. Manufacturing retention keeps Viridian close to product quality but may strain capacity. Negotiated rights are fairly standard; termination clauses unspecified but typically allow reversion鈥攑rotecting Viridian. Deal should be well-received by investors looking for continued non-dilutive financing.
Viridian Therapeutics (VRDN) ha presentato un modulo 8-K per comunicare un accordo di collaborazione e licenza firmato il 30 luglio 2025 con la giapponese Kissei Pharmaceutical, riguardante due anticorpi monoclonali IGF-1R, veligrotug e VRDN-003, per la malattia oculare tiroidea e altre potenziali indicazioni in Giappone. Kissei ottiene i diritti esclusivi di sviluppo e commercializzazione in Giappone e un diritto di produzione limitato non esclusivo; Viridian mantiene i diritti globali per gli altri territori e fornir脿 il prodotto.
Termini finanziari: Kissei pagher脿 un anticipo di 70 milioni di dollari. Viridian potr脿 ricevere fino a 315 milioni di dollari in milestone di sviluppo, regolatorie e di vendita. Dopo il lancio, saranno applicate royalty a scaglioni nella fascia dal basso 20% al medio 30% sulle vendite future in Giappone. Kissei finanzier脿 le attivit脿 cliniche, regolatorie e commerciali in Giappone sotto una supervisione congiunta, riducendo l'onere finanziario per Viridian.
Impatto strategico: L'accordo fornisce capitale immediato e non diluitivo, estende la liquidit脿 disponibile e convalida esternamente VRDN-003/veligrotug, preservando tutti i potenziali guadagni al di fuori del Giappone. I principali rischi di esecuzione includono la dipendenza dal successo dello sviluppo da parte di Kissei e gli obblighi continui di produzione di Viridian.
Viridian Therapeutics (VRDN) present贸 un formulario 8-K para revelar un acuerdo de colaboraci贸n y licencia firmado el 30 de julio de 2025 con la japonesa Kissei Pharmaceutical, que abarca dos anticuerpos monoclonales IGF-1R, veligrotug y VRDN-003, para la enfermedad ocular tiroidea y otras indicaciones potenciales en Jap贸n. Kissei recibe los derechos exclusivos de desarrollo y comercializaci贸n en Jap贸n y un derecho limitado de fabricaci贸n no exclusivo; Viridian mantiene los derechos globales fuera de Jap贸n y suministrar谩 el producto.
T茅rminos financieros: Kissei pagar谩 un anticipo de 70 millones de d贸lares. Viridian es elegible para recibir hasta 315 millones de d贸lares en hitos de desarrollo, regulatorios y de ventas. Despu茅s del lanzamiento, se aplicar谩n regal铆as escalonadas en un rango de bajo 20% a medio 30% sobre las ventas futuras en Jap贸n. Kissei financiar谩 las actividades cl铆nicas, regulatorias y comerciales en Jap贸n bajo una supervisi贸n conjunta, reduciendo la carga financiera de Viridian.
Impacto estrat茅gico: El acuerdo proporciona capital inmediato y no dilutivo, extiende la liquidez y valida externamente VRDN-003/veligrotug, preservando todo el potencial fuera de Jap贸n. Los principales riesgos de ejecuci贸n incluyen la dependencia del 茅xito del desarrollo por parte de Kissei y las obligaciones continuas de fabricaci贸n de Viridian.
Viridian Therapeutics(VRDN)電� 2025雲� 7鞗� 30鞚� 鞚茧掣 旮半皹鞚� Kissei Pharmaceutical瓿� 臧戩儊靹� 鞎堧硲歃� 氚� 旮绊儉 鞛犾灛鞝� 鞝侅潙歃濎潉 鞙勴暅 霊� 臧�歆� IGF-1R 雼伌搿犿暛觳挫澑 veligrotug鞕� VRDN-003鞐� 甏�頃� 順戨牓 氚� 霛检澊靹犾姢 瓿勳暯鞚� 觳搓舶頄堧嫟瓿� 8-K 氤搓碃靹滊ゼ 韱淀暣 瓿奠嫓頄堨姷雼堧嫟. 碍颈蝉蝉别颈电� 鞚茧掣 雮� 霃呾爯鞝� 臧滊皽 氚� 靸侅梾頇� 甓岆Μ鞕� 鞝滍暅鞝� 牍勲弲鞝愳爜 鞝滌“ 甓岆Μ毳� 攵�鞐皼鞙茧┌, Viridian鞚� 鞚茧掣 鞕� 鞝� 靹戈硠 甓岆Μ毳� 鞙犾頃橁碃 鞝滍拡鞚� 瓿店笁頃╇媹雼�.
鞛 臁瓣贝: 碍颈蝉蝉别颈电� 7,000毵� 雼煬鞚� 靹犽秷旮�鞚� 歆�旮夗暕雼堧嫟. Viridian鞚� 臧滊皽, 攴滌牅 氚� 韺愲Г 毵堨澕鞀ろ啢鞙茧 斓滊寑 3鞏� 1,500毵� 雼煬毳� 氚涭潉 鞛愱博鞚� 鞛堨姷雼堧嫟. 於滌嫓 頉� 鞚茧掣 雮� 氙鸽灅 毵れ稖鞐� 雽�頃� 20% 齑堧皹鞐愳劀 30% 欷戨皹雽�鞚� 雼硠氤� 搿滌棿韹�臧� 鞝侅毄霅╇媹雼�. 碍颈蝉蝉别颈电� 瓿惦彊 鞖挫榿 臧愲弲 頃橃棎 鞚茧掣 雮� 鞛勳儊, 攴滌牅 氚� 靸侅梾 頇滊彊鞚� 鞛愱笀 歆�鞗愴晿鞐� Viridian鞚� 順勱笀 攵�雼挫潉 欷勳瀰雼堧嫟.
鞝勲灥鞝� 鞓來枼: 鞚� 瓿勳暯鞚� 歃夑皝鞝侅澊瓿� 頋劃霅橃 鞎婋姅 鞛愲掣鞚� 鞝滉车頃橂┌, 順勱笀 鞖挫毄 旮瓣皠鞚� 鞐办灔頃橁碃 VRDN-003/veligrotug毳� 鞕鸽秬鞐愳劀 瓴�歃濏晿電� 霃欖嫓鞐� 鞚茧掣 鞕� 氇摖 鞛犾灛鞝� 鞚挫澋鞚� 氤挫〈頃╇媹雼�. 欤检殧 鞁ろ枆 鞙勴棙鞚� Kissei鞚� 臧滊皽 靹标车 鞚橃〈靹标臣 Viridian鞚� 歆�靻嶌爜鞚� 鞝滌“ 鞚橂鞛呺媹雼�.
Viridian Therapeutics (VRDN) a d茅pos茅 un formulaire 8-K pour divulguer un accord de collaboration et de licence sign茅 le 30 juillet 2025 avec la soci茅t茅 japonaise Kissei Pharmaceutical, portant sur deux anticorps monoclonaux IGF-1R, veligrotug et VRDN-003, destin茅s 脿 la maladie oculaire thyro茂dienne et 脿 d'autres indications potentielles au Japon. Kissei obtient les droits exclusifs de d茅veloppement et de commercialisation au Japon ainsi qu'un droit de fabrication limit茅 non exclusif ; Viridian conserve les droits mondiaux hors Japon et fournira le produit.
Conditions financi猫res : Kissei versera un paiement initial de 70 millions de dollars. Viridian peut recevoir jusqu'脿 315 millions de dollars en jalons de d茅veloppement, r茅glementaires et commerciaux. Des redevances 茅chelonn茅es allant de la plage basse des 20 % 脿 la moyenne des 30 % seront appliqu茅es sur les ventes futures au Japon apr猫s le lancement. Kissei financera les activit茅s cliniques, r茅glementaires et commerciales au Japon sous supervision conjointe, r茅duisant ainsi la charge financi猫re de Viridian.
Impact strat茅gique : Cet accord apporte un capital imm茅diat non dilutif, prolonge la tr茅sorerie disponible et valide ext茅rieurement VRDN-003/veligrotug tout en pr茅servant tous les avantages hors Japon. Les principaux risques d'ex茅cution incluent la d茅pendance au succ猫s du d茅veloppement par Kissei et les obligations continues de fabrication de Viridian.
Viridian Therapeutics (VRDN) hat eine 8-K-Meldung eingereicht, um eine am 30. Juli 2025 unterzeichnete Kooperations- und Lizenzvereinbarung mit dem japanischen Unternehmen Kissei Pharmaceutical offenzulegen. Diese betrifft zwei IGF-1R monoklonale Antik枚rper, veligrotug und VRDN-003, f眉r die Schilddr眉senaugenkrankheit und weitere potenzielle Indikationen in Japan. Kissei erh盲lt exklusive japanische Entwicklungs- und Vermarktungsrechte sowie ein begrenztes nicht-exklusives Herstellungsrecht; Viridian beh盲lt die globalen Rechte au脽erhalb Japans und wird das Produkt liefern.
Finanzielle Bedingungen: Kissei zahlt eine Vorauszahlung von 70 Millionen US-Dollar. Viridian kann bis zu 315 Millionen US-Dollar an Entwicklungs-, Zulassungs- und Verkaufsmeilensteinen erhalten. Nach Markteinf眉hrung folgen gestaffelte Lizenzgeb眉hren im niedrigen 20%- bis mittleren 30%-Bereich auf zuk眉nftige japanische Verk盲ufe. Kissei finanziert die klinischen, regulatorischen und kommerziellen Aktivit盲ten in Japan unter gemeinsamer Steuerung, was die finanzielle Belastung f眉r Viridian reduziert.
Strategische Auswirkungen: Die Vereinbarung bringt sofortiges, nicht verw盲sserndes Kapital, verl盲ngert die finanzielle Reichweite und validiert VRDN-003/veligrotug extern, w盲hrend alle Chancen au脽erhalb Japans erhalten bleiben. Wesentliche Ausf眉hrungsrisiken sind die Abh盲ngigkeit vom Entwicklungserfolg Kisseis und Viridians fortlaufende Herstellungsverpflichtungen.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01 | Entry into Material Definitive Agreements. |
Collaboration and License Agreement
On July 30, 2025, Viridian Therapeutics, Inc. (the “Company”) and Kissei Pharmaceutical Co., Ltd. (“Kissei”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) pursuant to which the Company granted to Kissei an exclusive license to develop and commercialize products containing veligrotug and VRDN-003, each differentiated humanized monoclonal antibodies targeting IGF-1R for potential treatments, including treatment of thyroid eye disease, in Japan, and a non-exclusive license to manufacture such licensed products worldwide for use in Japan under certain limited circumstances.
Under the terms of the Collaboration Agreement, the Company will receive an upfront payment of $70.0 million, and will be eligible to receive up to an additional $315.0 million upon the achievement of certain development, regulatory and sales milestones. The Company will also receive tiered royalties in percentages ranging from the twenties to the mid-thirties based on future net sales of licensed products as set forth in the Collaboration Agreement.
Kissei will be responsible for developing and seeking regulatory approval of the licensed products in Japan, subject to oversight from a joint steering committee. Following regulatory approval, Kissei will be responsible for commercializing the licensed products in Japan. Except in certain limited circumstances, the Company will be responsible for manufacturing and supplying the licensed products for Kissei’s developmental and commercial use in Japan.
The term of the Collaboration Agreement will expire in its entirety upon the expiration of the royalty term for all licensed products and satisfaction of certain payment obligations as set forth in the Collaboration Agreement, unless earlier terminated by the parties in accordance with the terms of the Collaboration Agreement.
The foregoing description of the terms of the Collaboration Agreement is not complete and is qualified in its entirety by reference to the text of the Collaboration Agreement, a copy of which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the period ended September 30, 2025.
| Item 7.01 | Regulation FD Disclosure |
On July 30, 2025, the Company issued a press release announcing entry into the Collaboration Agreement.
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.
| Item 9.01 | Exhibits |
(d) Exhibits.
| 99.1 | Press release, dated July 30, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Viridian Therapeutics, Inc. | ||||||
| Date: July 30, 2024 | By: | /s/ Stephen Mahoney | ||||
| Stephen Mahoney | ||||||
| President and Chief Executive Officer | ||||||
Source:
FAQ
What did Viridian Therapeutics (VRDN) announce in its 8-K?
How much upfront cash will VRDN receive from Kissei?
What is the total potential milestone value of the Kissei deal?
What royalty rate will Viridian earn on Japanese sales?
Who is responsible for development and commercialization in Japan?
Does Viridian retain rights outside Japan?
